The Investor
05 Aug 2026, 15:24
Eli Lilly (LLY) Stock Rises After Strong Q2 Earnings, Raises 2026 Guidance on Obesity Drug Strength
Eli Lilly (NYSE: LLY) shares gained around 2.4% on Wednesday after the pharmaceutical giant reported another quarter of exceptional financial results, raised its full-year 2026 guidance, and highlighted continued momentum across its blockbuster obesity and diabetes portfolio.
The earnings report was released as broader U.S. markets traded modestly higher. Investors looked past a weaker-than-expected ADP employment report and focused on stronger-than-expected S&P Global Services and Composite PMI data, which pointed to resilient business activity in the U.S. economy.
Revenue Jumps 48% as Mounjaro and Zepbound Continue to Drive Growth
Lilly reported second-quarter revenue of $23.0 billion, a 48% increase from the same period last year, driven primarily by strong demand for Mounjaro and Zepbound.
Key second-quarter results included:
* Revenue: $23.0 billion (+48% year over year)
* GAAP EPS: $7.94 (+26%)
* Non-GAAP EPS: $8.38 (+33%)
* GAAP net income: $7.1 billion (+25%)
The company said global sales volume increased 60% from a year earlier, more than offsetting lower realized prices. Revenue outside the United States surged 80%, reflecting accelerating international adoption of Mounjaro, while U.S. revenue rose 33%.
Gross margin improved to 85.8%, supported by favorable product mix and manufacturing efficiencies despite pricing pressure.
Lilly Raises Full-Year 2026 Guidance
One of the biggest catalysts for investors was management's improved outlook for the remainder of the year.
Lilly now expects:
* Full-year revenue of $85.0 billion to $87.0 billion
* Updated non-GAAP EPS guidance of $35.50 to $36.50
* Underlying operational EPS guidance increased by $2.78 at the midpoint before acquisition-related research and development charges
The raised guidance reflects management's confidence that demand for its leading diabetes and obesity medicines will remain strong throughout 2026.
Retatrutide and Pipeline Progress Strengthen Long-Term Outlook
Beyond current commercial performance, Lilly continued making significant progress across its pipeline.
The company announced positive Phase 3 data from three additional retatrutide obesity trials, completing the clinical package needed to support regulatory filings for obesity, obstructive sleep apnea, and knee osteoarthritis pain. Lilly plans to submit the treatment to the U.S. FDA during the first quarter of 2027.
Additional regulatory milestones included:
* FDA approval of Ebglyss for an expanded maintenance dosing schedule in atopic dermatitis.
* European Commission approval of Jaypirca for chronic lymphocytic leukemia across all treatment lines.
* Submission of oral GLP-1 candidate orforglipron for Type 2 diabetes in the United States.
Manufacturing Expansion and Acquisitions Support Future Growth
Lilly continued investing aggressively to expand its long-term growth platform.
During the quarter, the company completed acquisitions of Orna Therapeutics, Ajax Therapeutics, Centessa Pharmaceuticals, and Kelonia Therapeutics. After quarter-end, Lilly completed three additional acquisitions to build an infectious disease portfolio and also agreed to acquire AtaiBeckley.
The company also committed an additional $4.5 billion to expand manufacturing facilities in Indiana, further increasing production capacity for its rapidly growing product portfolio.
What Investors Are Watching
Wednesday's earnings reinforced Lilly's position as one of the pharmaceutical industry's strongest growth stories. Exceptional revenue growth, higher full-year guidance, continued leadership in the rapidly expanding obesity market, and a deep late-stage pipeline all strengthened investor confidence.
Going forward, investors will closely watch continued demand for Mounjaro and Zepbound, regulatory progress for retatrutide and orforglipron, integration of recent acquisitions, and whet
Eli Lilly (NYSE: LLY) shares gained around 2.4% on Wednesday after the pharmaceutical giant reported another quarter of exceptional financial results, raised its full-year 2026 guidance, and highlighted continued momentum across its blockbuster obesity and diabetes portfolio.
The earnings report was released as broader U.S. markets traded modestly higher. Investors looked past a weaker-than-expected ADP employment report and focused on stronger-than-expected S&P Global Services and Composite PMI data, which pointed to resilient business activity in the U.S. economy.
Revenue Jumps 48% as Mounjaro and Zepbound Continue to Drive Growth
Lilly reported second-quarter revenue of $23.0 billion, a 48% increase from the same period last year, driven primarily by strong demand for Mounjaro and Zepbound.
Key second-quarter results included:
* Revenue: $23.0 billion (+48% year over year)
* GAAP EPS: $7.94 (+26%)
* Non-GAAP EPS: $8.38 (+33%)
* GAAP net income: $7.1 billion (+25%)
The company said global sales volume increased 60% from a year earlier, more than offsetting lower realized prices. Revenue outside the United States surged 80%, reflecting accelerating international adoption of Mounjaro, while U.S. revenue rose 33%.
Gross margin improved to 85.8%, supported by favorable product mix and manufacturing efficiencies despite pricing pressure.
Lilly Raises Full-Year 2026 Guidance
One of the biggest catalysts for investors was management's improved outlook for the remainder of the year.
Lilly now expects:
* Full-year revenue of $85.0 billion to $87.0 billion
* Updated non-GAAP EPS guidance of $35.50 to $36.50
* Underlying operational EPS guidance increased by $2.78 at the midpoint before acquisition-related research and development charges
The raised guidance reflects management's confidence that demand for its leading diabetes and obesity medicines will remain strong throughout 2026.
Retatrutide and Pipeline Progress Strengthen Long-Term Outlook
Beyond current commercial performance, Lilly continued making significant progress across its pipeline.
The company announced positive Phase 3 data from three additional retatrutide obesity trials, completing the clinical package needed to support regulatory filings for obesity, obstructive sleep apnea, and knee osteoarthritis pain. Lilly plans to submit the treatment to the U.S. FDA during the first quarter of 2027.
Additional regulatory milestones included:
* FDA approval of Ebglyss for an expanded maintenance dosing schedule in atopic dermatitis.
* European Commission approval of Jaypirca for chronic lymphocytic leukemia across all treatment lines.
* Submission of oral GLP-1 candidate orforglipron for Type 2 diabetes in the United States.
Manufacturing Expansion and Acquisitions Support Future Growth
Lilly continued investing aggressively to expand its long-term growth platform.
During the quarter, the company completed acquisitions of Orna Therapeutics, Ajax Therapeutics, Centessa Pharmaceuticals, and Kelonia Therapeutics. After quarter-end, Lilly completed three additional acquisitions to build an infectious disease portfolio and also agreed to acquire AtaiBeckley.
The company also committed an additional $4.5 billion to expand manufacturing facilities in Indiana, further increasing production capacity for its rapidly growing product portfolio.
What Investors Are Watching
Wednesday's earnings reinforced Lilly's position as one of the pharmaceutical industry's strongest growth stories. Exceptional revenue growth, higher full-year guidance, continued leadership in the rapidly expanding obesity market, and a deep late-stage pipeline all strengthened investor confidence.
Going forward, investors will closely watch continued demand for Mounjaro and Zepbound, regulatory progress for retatrutide and orforglipron, integration of recent acquisitions, and whet
